Special Symposium 1
EANM and EARL
Sunday, October 20, 09:45 - 11:15

Session Title
Harmonisation - The Path For New Criteria and New Accreditations

Chairpersons
Caroline Stokke (Oslo, Norway)
Andres Kaalep (Tallinn, Estonia)

Programme

09:45 - 10:05 **Josee M Zijlstra** (Amsterdam, Netherlands): Onco accreditation updates e.g. TMTV

10:05 - 10:20 **Mahnaz Shekari** (Barcelona, Spain): EARL's new Brain PET/CT accreditation – methodology confirmation

10:20 - 10:35 **Nelleke Tolboom** (Utrecht, Netherlands): Clinical benefits of PET/CT brain accreditation

10:35 - 11:00 **John Dickson** (London, United Kingdom): SPECT accreditation

10:45 - 11:15 Q&A, Discussion

Educational Objectives
1. Learn about updates to EARL Wholebody FDG PET/CT accreditation and its benefits in oncology imaging.
2. Understand the processes involved in EARLs new Brain PET/CT accreditation and the benefits it will bring to your clinic.
3. Know more about EARL 177Lu SPECT accreditation, the process and see the first results from the process.

Summary
Accreditation in nuclear medicine imaging provides certainty in the quality of imaging outputs and biomarkers, both for multi-centre trials and clinically. EARL has had success at setting accreditation standards in oncology PET imaging, and more recently in neuro PET imaging and SPECT. In this session, updates on Wholebody FDG PET/CT will be presented, its clinical benefits, and its use for deriving different metrics such as Total Metabolic Tumour Volume (TMTV). Brain imaging accreditation is a recent initiative by EARL, and the session will both describe and confirm the methodology used in the accreditation process before describing the benefits it can bring to your clinic. Finally, with the growth of theranostics and radioligand therapy dosimetry, EARLs 177Lu SPECT accreditation process will be presented together with some challenges specific to SPECT imaging, and some results from the first centres going through the process.

Key Words
Accreditation; FDG Oncology; FDG Brain; 177Lu SPECT